Diminazene attenuates pulmonary hypertension and improves angiogenic progenitor cell functions in experimental models

American Journal of Respiratory and Critical Care Medicine

Volumn 187, Issue 6, 2013, Pages 648-657

  Shenoy, Vinayak ^a   Gjymishka, Altin ^a   Jarajapu, Yagna P ^a   Qi, Yanfei ^a   Afzal, Aqeela ^b   Rigatto, Katya ^a   Ferreira, Anderson J ^c   Fraga Silva, Rodrigo A ^c   Kearns, Patrick ^a   Douglas, Jane Yellowlees ^a   Agarwal, Deepmala ^d   Mubarak, Kamal K ^b   Bradford, Chastity ^a   Kennedy, William R ^a   Jun, Joo Y ^a   Rathinasabapathy, Anandharajan ^a   Bruce, Erin ^a   Gupta, Dipankar ^b   Cardounel, Arturo J ^e   Mocco, J ^b   Patel, Jawaharlal M ^b,f   Francis, Joseph ^d   Grant, Maria B ^a   Katovich, Michael J ^a   Raizada, Mohan K ^a   more..

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^d LOUISIANA STATE UNIVERSITY   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

ACE2; Angiogenic progenitor cells; Diminazen; Pulmonary hypertension

Indexed keywords

BLEOMYCIN; C 16; DIMINAZENE ACETURATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MONOCROTALINE; STROMAL CELL DERIVED FACTOR 1ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL FUNCTION; CELL ISOLATION; CONTROLLED STUDY; DISEASE COURSE; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; EXPERIMENTAL MODEL; HEART FUNCTION; HOMEOSTASIS; HUMAN; HUMAN CELL; HYPOXIA; IN VITRO STUDY; MALE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT; STEM CELL;

ANIMALS; CELL MIGRATION ASSAYS; DIMINAZENE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; HYPERTENSION, PULMONARY; MALE; NEOVASCULARIZATION, PHYSIOLOGIC; RATS; RATS, SPRAGUE-DAWLEY; RENIN-ANGIOTENSIN SYSTEM; STEM CELLS; TRYPANOCIDAL AGENTS;

EID: 84875133413     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201205-0880OC     Document Type: Article

References (53)

1. Schermuly RT, Ghofrani HA, Wilkins MR, Grimminger F. Mechanisms of disease: pulmonary arterial hypertension. Nat Rev Cardiol 2011;8: 443-455.
2. Nathan SD, Noble PW, Tuder RM. Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots. Am J Respir Crit Care Med 2007;175:875-880.
3. O'Callaghan DS, Savale L, Montani D, Jaïs X, Sitbon O, Simonneau G, Humbert M. Treatment of pulmonary arterial hypertension with targeted therapies. Nat Rev Cardiol 2011;8:526-538.
4. Raizada MK, Ferreira AJ. ACE2: a new target for cardiovascular disease therapeutics. J Cardiovasc Pharmacol 2007;50:112-119.
5. Yamazato Y, Ferreira AJ, Hong KH, Sriramula S, Francis J, Yamazato M, Yuan L, Bradford CN, Shenoy V, Oh SP, et al. Prevention of pulmonary hypertension by angiotensin-converting enzyme-2 gene transfer. Hypertension 2009;54:365-371.
6. Shenoy V, Ferreira AJ, Qi Y, Fraga-Silva RA, Díez-Freire C, Dooies A, Jun JY, Sriramula S, Mariappan N, Pourang D, et al. The angiotensinconverting enzyme 2/angiotensin-(1-7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 2010;182:1065-1072.
7. Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, Yang P, Sarao R, Wada T, Leong-Poi H, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 2005;436:112-116.
8. Zisman LS, Keller RS, Weaver B, Lin Q, Speth R, Bristow MR, Canver CC. Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme Homologue ACE2. Circulation 2003;108:1707-1712.
9. Shenoy V, Qi Y, Katovich MJ, Raizada MK. ACE2, a promising therapeutic target for pulmonary hypertension. Curr Opin Pharmacol 2011;11:150-155.
10. Oudit GY, Penninger JM. Recombinant human angiotensin-converting enzyme 2 as a new renin-angiotensin system peptidase for heart failure therapy. Curr Heart Fail Rep 2011;8:176-183.
11. Iwata M, Cowling RT, Yeo SJ, Greenberg B. Targeting the ACE2-Ang-(1-7) pathway in cardiac fibroblasts to treat cardiac remodeling and heart failure. J Mol Cell Cardiol 2011;51:542-547.
12. Kulemina LV, Ostrov DA. Prediction of off-target effects on angiotensinconverting enzyme 2. J Biomol Screen 2011;16:878-885.
13. Abaru DE, Liwo DA, Isakina D, Okori EE. Retrospective long-term study of effects of Berenil by follow-up of patients treated since 1965. Tropenmed Parasitol 1984;35:148-150.
14. Raether W, Hajdu P, Seidenath H, Damm D. Pharmacokinetic and chemoprophylactic studies on Berenil in Wistar rats. Z Tropenmed Parasitol 1974;23:418-427.
15. Toshner M, Voswinckel R, Southwood M, Al-Lamki R, Howard LS, Marchesan D, Yang J, Suntharalingam J, Soon E, Exley A, et al. Evidence of dysfunction of endothelial progenitors in pulmonary arterial hypertension. Am J Respir Crit Care Med 2009;180:780-787.
16. Junhui Z, Xingxiang W, Guosheng F, Yunpeng S, Furong Z, Junzhu C. Reduced number and activity of circulating endothelial progenitor cells in patients with idiopathic pulmonary arterial hypertension. Respir Med 2008;102:1073-1079.
17. Marsboom G, Pokreisz P, Gheysens O, Vermeersch P, Gillijns H, Pellens M, Liu X, Collen D, Janssens S. Sustained endothelial progenitor cell dysfunction after chronic hypoxia-induced pulmonary hypertension. Stem Cells 2008;26:1017-1026.
18. Zhao YD, Courtman DW, Deng Y, Kugathasan L, Zhang Q, Stewart DJ. Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease. Circ Res 2005;96:442-450.
19. Shenoy V, Yagna J, Gjymishka A, Afzal A, Rigatto K, Qi Y, Bradford C, Ely D, Kearns P, Carrie R, et al. An ACE2 activator (DIZE) improves endothelial progenitor cell function in patients with pulmonary hypertension. Circulation 2011;124:A13757.
20. Dorfmüller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial hypertension. Eur Respir J 2003;22:358-363.
21. Soon E, Holmes AM, Treacy CM, Doughty NJ, Southgate L, Machado RD, Trembath RC, Jennings S, Barker L, Nicklin P, et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation 2010;122:920-927.
22. Dales NA, Gould AE, Brown JA, Calderwood EF, Guan B, Minor CA, Gavin JM, Hales P, Kaushik VK, StewartM, et al. Substrate-based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) inhibitors. J Am Chem Soc 2002;124:11852-11853.
23. Valarmathi MT, Davis JM, Yost MJ, Goodwin RL, Potts JD. A threedimensional model of vasculogenesis. Biomaterials 2009;30:1098-1112.
24. Busik JV, Tikhonenko M, Bhatwadekar A, Opreanu M, Yakubova N, Caballero S, Player D, Nakagawa T, Afzal A, Kielczewski J, et al. Diabetic retinopathy is associated with bone marrow neuropathy and a depressed peripheral clock. J Exp Med 2009;206:2897-2906.
25. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997;275:964-967.
26. Kawamoto A, Iwasaki H, Kusano K,Murayama T, Oyamada A, Silver M, Hulbert C, Gavin M, Hanley A, Ma H, et al. CD34-positive cells exhibit increased potency and safety for therapeutic neovascularization after myocardial infarction compared with total mononuclear cells. Circulation 2006;114:2163-2169.
27. Tei K, Matsumoto T, Mifune Y, Ishida K, Sasaki K, Shoji T, Kubo S, Kawamoto A, Asahara T, Kurosaka M, et al. Administrations of peripheral blood CD34-positive cells contribute to medial collateral ligament healing via vasculogenesis. Stem Cells 2008;26:819-830.
28. Blocklet D, Toungouz M, Berkenboom G, Lambermont M, Unger P, Preumont N, Stoupel E, Egrise D, Degaute JP, Goldman M, et al. Myocardial homing of nonmobilized peripheral-blood CD341 cells after intracoronary injection. Stem Cells 2006;24:333-336.
29. Losordo DW, Henry TD, Davidson C, Sup Lee J, Costa MA, Bass T, Mendelsohn F, Fortuin FD, Pepine CJ, Traverse JH, et al. ACT34-CMI Investigators. Intramyocardial, autologous CD341 cell therapy for refractory angina. Circ Res 2011;109:428-436.
30. Heringer-Walther S, Eckert K, Schumacher SM, Uharek L, Wulf-Goldenberg A, Gembardt F, Fichtner I, Schultheiss HP, Rodgers K, Walther T. Angiotensin-(1-7) stimulates hematopoietic progenitor cells in vitro and in vivo. Haematologica 2009;94:857-860.
31. Ellefson DD, diZerega GS, Espinoza T, Roda N, Maldonado S, Rodgers KE. Synergistic effects of co-administration of angiotensin-(1-7) and Neupogen on hematopoietic recovery in mice. Cancer Chemother Pharmacol 2004;53:15-24.
32. Bradley SP, Auger WR, Moser KM, Fedullo PF, Channick RN, Bloor CM. Right ventricular pathology in chronic pulmonary hypertension. Am J Cardiol 1996;78:584-587.
33. Bogaard HJ, Abe K, Vonk Noordegraaf A, Voelkel NF. The right ventricle under pressure: cellular and molecular mechanisms of rightheart failure in pulmonary hypertension. Chest 2009;135:794-804.
34. Rey-Parra GJ, Vadivel A, Coltan L, Hall A, Eaton F, Schuster M, Loibner H, Penninger JM, Kassiri Z, Oudit GY, et al. Angiotensin converting enzyme 2 abrogates bleomycin-induced lung injury. J Mol Med 2012;90:637-647.
35. Li X, Molina-Molina M, Abdul-Hafez A, Uhal V, Xaubet A, Uhal BD. Angiotensin converting enzyme-2 is protective but downregulated in human and experimental lung fibrosis. Am J Physiol Lung Cell Mol Physiol 2008;295:L178-L185.
36. Patel NM, Lederer DJ, Borczuk AC, Kawut SM. Pulmonary hypertension in idiopathic pulmonary fibrosis. Chest 2007;132:998-1006.
37. Nadrous HF, Pellikka PA, Krowka MJ, Swanson KL, Chaowalit N, Decker PA, Ryu JH. The impact of pulmonary hypertension on survival in patients with idiopathic pulmonary fibrosis. Chest 2005;128: 616S-617S.
38. Rubin LJ, Badesch DB. Evaluation and management of the patient with pulmonary arterial hypertension. Ann Intern Med 2005;143:282-292.
39. Hassoun PM, Mouthon L, Barberà JA, Eddahibi S, Flores SC, Grimminger F, Jones PL, Maitland ML, Michelakis ED, Morrell NW, et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 2009;54(Suppl)S10-S19.
40. Humbert M, Monti G, Brenot F, Sitbon O, Portier A, Grangeot-Keros L, Duroux P, Galanaud P, Simonneau G, Emilie D. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 1995;151:1628-1631.
41. Fujita M, Mason RJ, Cool C, Shannon JM, Hara N, Fagan KA. Pulmonary hypertension in TNF-alpha-overexpressing mice is associated with decreased VEGF gene expression. J Appl Physiol 2002;93:2162-2170.
42. Zaiman AL, Podowski M, Medicherla S, Gordy K, Xu F, Zhen L, Shimoda LA, Neptune E, Higgins L, Murphy A, et al. Role of TGFβ/ALK5 kinase in monocrotaline-induced pulmonary hypertension. Am J Respir Crit Care Med 2008;177:896-905.
43. Drakopanagiotakis F, Xifteri A, Polychronopoulos V, Bouros D. Apoptosis in lung injury and fibrosis. Eur Respir J 2008;32:1631-1638.
44. Uhal BD, Abdul-Hafez A. Angiotensin II in apoptotic lung injury: potential role in meconium aspiration syndrome. J Perinatol 2008;S108-S112.
45. Uhal BD, Li X, Piasecki CC, Molina-Molina M. Angiotensin signaling in pulmonary fibrosis. Int J Biochem Cell Biol 2012;44:465-468.
46. Uhal BD, Li X, Xue A, Gao X, Abdul-Hafez A. Regulation of alveolar epithelial cell survival by the ACE-2/angiotensin 1-7/Mas axis. Am J Physiol Lung Cell Mol Physiol 2011;301:L269-L274.
47. Ferreira AJ, Shenoy V, Yamazato Y, Sriramula S, Francis J, Yuan L, Castellano RK, Ostrov DA, Oh SP, Katovich MJ, et al. Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension. Am J Respir Crit Care Med 2009; 179:1048-1054.
48. Santos RA, Ferreira AJ, Pinheiro SV, SampaioWO, Touyz R, Campagnole-Santos MJ. Angiotensin-(1-7) and its receptor as a potential targets for new cardiovascular drugs. Expert Opin Investig Drugs 2005;14: 1019-1031.
49. Mirsky R, Jahn S, Koskenvuo JW, Sievers RE, Yim SM, Ritner C, Bernstein HS, Angeli FS, Boyle AJ, De Marco T, et al. Treatment of pulmonary arterial hypertension with circulating angiogenic cells. Am J Physiol Lung Cell Mol Physiol 2011;301:L12-L19.
50. Toshner M, Morrell NW. Endothelial progenitor cells in pulmonary hypertension: dawn of cell-based therapy? Int J Clin Pract Suppl 2010; 165:7-12.
51. Fadini GP, Avogaro A, Ferraccioli G, Agostini C. Endothelial progenitors in pulmonary hypertension: new pathophysiology and therapeutic implications. Eur Respir J 2010;35:418-425.
52. Pilch DS, Kirolos MA, Liu X, Plum GE, Breslauer KJ. Berenil [1,3-bis (4′-amidinophenyl)triazene] binding to DNA duplexes and to a RNA duplex: evidence for both intercalative and minor groove binding properties. Biochemistry 1995;34:9962-9976.
53. Portugal J. Berenil acts as a poison of eukaryotic topoisomerase II. FEBS Lett 1994;344:136-138.